Cargando…
Long-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studies
OBJECTIVE: This study aimed to evaluate the long-term safety and efficacy of olokizumab (OKZ), an anti-interleukin (IL)-6 monoclonal antibody, in patients with rheumatoid arthritis (RA) and inadequate response to tumor necrosis factor-alpha inhibitors. METHODS: Eligible patients completed study RA00...
Autores principales: | Genovese, Mark C., Durez, Patrick, Fleischmann, Roy, Tanaka, Yoshiya, Furst, Daniel, Yamanaka, Hisashi, Korneva, Elena, Vasyutin, Igor, Takeuchi, Tsutomu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medical Research and Education Association
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9770405/ https://www.ncbi.nlm.nih.gov/pubmed/34101570 http://dx.doi.org/10.5152/eurjrheum.2021.19207 |
Ejemplares similares
-
Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study
por: Genovese, Mark C, et al.
Publicado: (2014) -
Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study
por: Feist, Eugen, et al.
Publicado: (2022) -
Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study
por: Nasonov, Evgeniy, et al.
Publicado: (2022) -
Analysis of miRNA Expression in Patients with Rheumatoid Arthritis during Olokizumab Treatment
por: Bure, Irina V., et al.
Publicado: (2020) -
Genetic and Clinical Factors Associated with Olokizumab Treatment in Russian Patients with Rheumatoid Arthritis
por: Mikhaylenko, Dmitry S., et al.
Publicado: (2022)